- Home
- VELO vs PROK Comparison
VELO vs PROK Comparison
Compare VELO & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VELO | PROK |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | 134 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 306.0M | 359.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | VELO | PROK |
|---|---|---|
| Price | $25.41 | $1.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $18.00 | $7.40 |
| AVG Volume (30 Days) | ★ 2.9M | 739.0K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $42.22 | N/A |
| Revenue Next Year | $50.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $2.87 | $0.54 |
| 52 Week High | $25.73 | $7.13 |
Technical Indicators
Market Signals| Indicator | VELO | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 72.71 | 49.49 |
| Support Level | $12.06 | $1.73 |
| Resistance Level | N/A | $2.58 |
| Average True Range (ATR) | 2.69 | 0.12 |
| MACD | 0.89 | 0.01 |
| Stochastic Oscillator | 96.96 | 60.23 |
Price Performance
Historical ComparisonAbout VELO Velo3D Inc.
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.